Publications by authors named "Markus Cybulla"

Claim this Profile
I
Impact of migalastat on cerebral outcomes in fabry disease - results from the prospective observational FAMOUS trial.
Momoko Choudhury, Malte Lenders, Pauline Laufer, Max Masthoff, Sima Canaan-Kühl, Markus Cybulla

Neurol Res Pract· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of enzyme replacement therapy and migalastat on disease progression in females with fabry disease.
Malte Lenders, Albina Nowak, Markus Cybulla, Jessica Kaufeld, Anja Friederike Köhn

Orphanet J Rare Dis· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relevance of Neutralizing Antibodies for the Pharmacokinetics of Pegunigalsidase Alfa in Patients with Fabry Disease.
Malte Lenders, Elise Raphaela Menke, Michael Rudnicki, Markus Cybulla, Eva Brand

BioDrugs· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of enzyme replacement therapy on clinical manifestations in females with Fabry disease.
Malte Lenders, Albina Nowak, Markus Cybulla, Jessica Kaufeld, Anja Friederike Köhn

Orphanet J Rare Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: A prospective, multicenter study.
Jonas Müntze, Kolja Lau, Markus Cybulla, Eva Brand, Tereza Cairns

Mol Genet Metab· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renoprotective Effect of Agalsidase Alfa: A Long-Term Follow-Up of Patients with Fabry Disease.
Markus Cybulla, Kathleen Nicholls, Sandro Feriozzi, Aleš Linhart, Joan Torras

J Clin Med· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Fabry Disease management with migalastat-outcome from a prospective 24 months observational multicenter study (FAMOUS).
Malte Lenders, Peter Nordbeck, Christine Kurschat, Maria Eveslage, Nesrin Karabul, Markus Cybulla

Eur Heart J Cardiovasc Pharmacother· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells.
Anke Schumann, Kristin Schaller, Véronique Belche, Markus Cybulla, Sarah C Grünert

J Inherit Metab Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Fabry's Disease With Migalastat: Outcome From a Prospective Observational Multicenter Study (FAMOUS).
Malte Lenders, Peter Nordbeck, Christine Kurschat, Nesrin Karabul, Jessica Kaufeld, Markus Cybulla

Clin Pharmacol Ther· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Malte Lenders, Leon Paul Neußer, Michael Rudnicki, Peter Nordbeck, Sima Canaan-Kühl, Markus Cybulla

J Am Soc Nephrol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dysregulated autophagy contributes to podocyte damage in Fabry's disease.
Max C Liebau, Fabian Braun, Katja Höpker, Claudia Weitbrecht, Valerie Bartels, Markus Cybulla

PLoS One· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.
Markus Cybulla, Christine Kurschat, Michael West, Kathy Nicholls, Joan Torras

J Nephrol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology of autosomal-dominant polycystic kidney disease: an in-depth clinical study for south-western Germany.
Hartmut P H Neumann, Cordula Jilg, Janina Bacher, Zinaida Nabulsi, Angelica Malinoc, Markus Cybulla

Nephrol Dial Transplant· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adult patients with sporadic polycystic kidney disease: the importance of screening for mutations in the PKD1 and PKD2 genes.
Hartmut P H Neumann, Janina Bacher, Zinaida Nabulsi, Nadine Ortiz Brüchle, Michael M Hoffmann, Markus Cybulla

Int Urol Nephrol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effectiveness of long-term agalsidase alfa therapy in the treatment of Fabry nephropathy.
Sandro Feriozzi, Joan Torras, Markus Cybulla, Kathy Nicholls, Gere Sunder-Plassmann

Clin J Am Soc Nephrol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Agalsidase alfa slows the decline in renal function in patients with Fabry disease.
Sandro Feriozzi, Andreas Schwarting, Gere Sunder-Plassmann, Michael West, Markus Cybulla

Am J Nephrol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alu-Alu recombination underlies the vast majority of large VHL germline deletions: Molecular characterization and genotype-phenotype correlations in VHL patients.
Gerlind Franke, Birke Bausch, Michael M Hoffmann, Markus Cybulla, Christian Wilhelm

Hum Mutat· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney transplantation in patients with Fabry disease.
Markus Cybulla, Kerstin Nanette Walter, Andreas Schwarting, Raffaelle Divito, Sandro Feriozzi

Transpl Int· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic and clinical investigation of pheochromocytoma: a 22-year experience, from Freiburg, Germany to international effort.
Birke Bausch, Carsten C Boedeker, Ansgar Berlis, Ingo Brink, Markus Cybulla

Ann N Y Acad Sci· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene.
Francesca Schiavi, Carsten C Boedeker, Birke Bausch, Mariola Peçzkowska, Clara Fuentes Gomez, Markus Cybulla

JAMA· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic renal failure and proteinuria in adulthood: Fabry disease predominantly affecting the kidneys.
Markus Cybulla, Ellen Schaefer, Susanne Wendt, Hao Ling, Stefan M Kröber

Am J Kidney Dis· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New genetic causes of pheochromocytoma: current concepts and the clinical relevance.
Hartmut P H Neumann, Markus Cybulla, Hirotaka Shibata, Mototsugu Oya, Mitsuhide Naruse

Keio J Med· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
When to look for Von Hippel-Lindau disease in gastroenteropancreatic neuroendocrine tumors?
Hao Ling, Markus Cybulla, Oliver Schaefer, Christian Arnold, Marcus Schories

Neuroendocrinology· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal toxicity after radionuclide therapy.
Bieke Lambert, Markus Cybulla, Stefan M Weiner, Christophe Van De Wiele, Hamphrey Ham

Radiat Res· May 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
90Y-DOTATOC and nephrotoxicity.
Andreas Otte, Markus Cybulla, Stefan M Weiner

Eur J Nucl Med Mol Imaging· November 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis